CPB reports its fiscal Q4 results on September 2 with one of the more striking positioning shifts in the packaged-food sector — short sellers have been covering aggressively, even as the stock remains well below where it traded a year ago.
Short interest tells the most interesting story heading into the print. Bears have pulled back sharply, with SI dropping 17% in a single week to 13.7% of the free float — still elevated in absolute terms, but the direction is unambiguous. The coverage wave accelerated around August 24, when positions fell from roughly 48 million shares to just over 41 million in a matter of days. The ORTEX short score eased from 75.3 to 73.6 over the same period, confirming the retreat. Days to cover remain high at 9.1, so the remaining short base is still meaningful. But the trend is clear: bears are reducing exposure ahead of the print, not adding to it.
Options positioning adds a modest counterpoint. The put/call ratio ticked up to 0.70 on August 31 — two standard deviations above its 20-day average of 0.67, the highest defensive reading in weeks. That's a small but notable divergence: while short sellers cover, options traders have quietly added a layer of downside protection. Borrow availability has actually loosened over the past week, rising to 72% from roughly 62% — still in the tight-to-normal range, but easing alongside the short covering. Cost to borrow has fallen 21% on the week to 2.3%, reflecting reduced demand for borrows rather than any change in share supply.
The analyst community is cautious but not outright negative — and the direction of travel this month has been mildly constructive. JPMorgan raised its target to $22 from $20 while staying Neutral, and TD Cowen lifted to $22 from $20 with a Hold. Evercore, also on August 31, trimmed its target by a dollar to $22, keeping an In-Line rating. UBS remains the outlier, holding a Sell with an $18 target — a level well below where the stock trades at $23.68. The mean price target of $21.88 sits modestly below the current price, which itself is notable: the stock has gained 7.7% over the past month, leaving it marginally ahead of where most of the Street thinks fair value lies. The bull case rests on Campbell's brand portfolio and M&A optionality at roughly 9x EV/EBITDA. Bears point to revenue softness, margin compression, and downward EPS revisions — with momentum and earnings estimate scores ranking in the bottom quartile of the universe.
Ownership adds one distinctive wrinkle. The Dorrance family — the founding dynasty — controls a substantial and stable stake, with the Mary Alice Dorrance Malone Revocable Trust recently filing a 13G showing a stake that grew to 10.2% of the class. BlackRock also filed a 13G/A in July, lifting its disclosed position to 9.1% from 5.3%. Neither holder is an activist, and the disclosure caveat applies — stakes are as last disclosed around the 5% threshold. Still, the concentration of long-term family and institutional ownership provides a structural floor that short sellers are increasingly having to price in.
The print will test whether Campbell's volume trajectory has stabilised enough to justify the recent rally — and whether a structurally cautious Street can find reason to move off its cluster of $21–$22 targets.
See the live data behind this article on ORTEX.
Open CPB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
